Skip to main content
Equibles
PRLD logo

PRLD · Prelude Therapeutics Inc · Metrics

Track PRLD — free

Use PRLD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRLD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.88 +0.18 (+4.86%) At close · Oct 27 Q3 2025 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$295.27M
Shares
79.80M
Volume · Oct 27 277.22K Avg daily vol (3M) 518.04K

PRLD metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.88
Market cap
$295.27M

Price action

20 metrics
Price change (1W)
+9.1%
Price change (30D)
-5.4%
Price change (3M)
-4.9%
Price change (6M)
-18.1%
Price change (YTD)
+27.6%
Price change (1Y)
+128.4%
Trailing year
Price change (5Y)
-79.0%
52-week high
$6.63
52-week low
$1.19
Change from 52-week high
-44.2%
Change from 52-week low
+210.9%
Annualized volatility
195.7%
Annualized volatility (3M)
84.3%
Beta
1.9
RSI (14D)
44.2
Price vs SMA 50
-19.7%
Price vs SMA 200
-7.0%
Avg volume (3M)
516,535
Relative volume
0.5
Average dollar volume
$2.45M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
79.80M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
6.2×
reciprocal yield 16.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
12.9×
reciprocal yield 7.7%
P / book
2.2
reciprocal yield 46.2%
FCF yield
-11.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-20.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-10

Profitability

9 metrics
Gross margin
—
Operating margin
-300.6%
Trailing 12 months
Net margin
-269.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$67.40M
Net income (TTM)
−$60.49M
Trailing 12 months
Diluted EPS (TTM)
$-0.73
FCF margin
-148.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.27
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.81
EBITDA per diluted share (TTM)
$-0.80
Net income per diluted share (TTM)
$-0.73
Operating cash flow per diluted share (TTM)
$-0.38
Free cash flow per diluted share (TTM)
$-0.38
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.84
Stock compensation per diluted share (TTM)
$0.10
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+73.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$22.42M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+29.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-45.2%
Return on assets
-31.9%
Debt / equity
0.0
Current ratio
4.1
EBITDA (TTM)
−$65.81M
Free cash flow (TTM)
−$33.26M
Quick ratio
4.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$151.76M
Latest balance sheet
Cash & equivalents
$26.33M
Total assets
$189.36M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$33.26M
Capital expenditures (TTM)
$0
R&D (TTM)
$69.43M
SG&A (TTM)
—
Stock compensation (TTM)
$8.29M
R&D / revenue
309.6%
Stock compensation / revenue
37.0%

Ownership (13F)

9 metrics
13F filers
77
13F filer change QoQ
+22
Institutional ownership
62.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
52.5%
Private-fund adviser ownership
48.2%
Active holders' share change QoQ
+54.3%
Holder tenure
14.4
Price vs estimated holder cost
+33.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.3%

Short interest

3 metrics
Short interest
6.4%
Latest settlement · 11.5 days to cover
Days to cover
11.5d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1678660 CUSIP 74065P101 13F (30d) 6 filings 6 filers Visit website Investor relations